In particular, neurofilament light chain measurement has shown promise as a biomarker for disease activity: serum concentration correlates with new T2 and gadolinium-enhancing lesions on MRI, indicative of disease activity from active inflammation, and therefore may have some predictive value for disease progression; however, many confounding factors influence serum neurofilament light chain concentration, and further research is required to establish its prognostic value in patients with progressive and non-progressive MS phenotypes [33]. The gene discussed is NEFL; the disease is myeloid sarcoma.